Medicaid reimbursement for prenatal smoking intervention influences quitting and cessation

R Petersen, J M Garrett, C L Melvin and K E Hartmann

*Tob. Control* 2006;15;30-34
doi:10.1136/tc.2005.012187

Updated information and services can be found at:
http://tc.bmjjournals.com/cgi/content/full/15/1/30

These include:

**References**
This article cites 27 articles, 7 of which can be accessed free at:
http://tc.bmjjournals.com/cgi/content/full/15/1/30#BIBL

**Rapid responses**
You can respond to this article at:
http://tc.bmjjournals.com/cgi/eletter-submit/15/1/30

**Email alerting service**
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

**Topic collections**
Articles on similar topics can be found in the following collections

- Smoking (978 articles)
- Smoking cessation (221 articles)

**Notes**

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to *Tobacco Control* go to:
http://www.bmjjournals.com/subscriptions/
RESEARCH PAPER

Medicaid reimbursement for prenatal smoking intervention influences quitting and cessation

R Petersen, J M Garrett, C L Melvin, K E Hartmann

Background: 40% of births in the USA are covered by Medicaid and smoking is prevalent among recipients. The objective of this study was to evaluate the association between levels of Medicaid coverage for prenatal smoking cessation interventions on quitting during pregnancy and maintaining cessation after delivery.

Methods: Population based survey study of 7513 post-partum women from 15 states who: participated in Pregnancy Risk Assessment Monitoring System (PRAMS) during 1998–2000; smoked at the beginning of their pregnancy; and had Medicaid coverage. Participating states were categorised into three levels of Medicaid coverage for smoking cessation interventions during prenatal care: extensive (pharmacotherapies and counselling); some (pharmacotherapies or counselling); or none. Quit rates among women who smoked before pregnancy and rates of maintaining cessation were examined.

Results: Higher levels of coverage during prenatal care for smoking cessation interventions were associated with higher quit rates; 51%, 43%, and 39% of women quit in states with extensive, some, and no coverage, respectively. Compared to women in states with no coverage, women in states with extensive coverage had 1.6 times the odds of quitting smoking (odds ratio (OR) 1.58, 95% confidence interval (CI) 1.00 to 2.49). Maintenance of cessation after delivery was associated with extensive levels of Medicaid coverage; 48% of women maintained cessation in states with extensive coverage compared to 37% of women in states with no coverage. Compared to women in states with no coverage, women with extensive coverage had 1.6 times the odds of maintaining cessation (OR 1.63, 95% CI 1.04 to 2.56).

Conclusions: Prenatal Medicaid coverage for both pharmacotherapies and counselling is associated with higher rates of quitting and continued cessation. This suggests policymakers can promote cessation by broadening smoking cessation services in Medicaid prenatal care.

The adverse health and economic impact of smoking during pregnancy is well established. Smoking among pregnant women has implications for the Medicaid system as it covers prenatal and birth costs for approximately 40% of births in the USA, and women who receive Medicaid are 2.5 times more likely to smoke during pregnancy than women who do not receive Medicaid. Effective smoking cessation interventions for use during prenatal care include counselling (for example, individual, group, or telephone) and pharmacotherapies (for example, over the counter and prescription). Counselling has been recommended as especially appropriate for pregnant women due to the controversy of whether or not pharmacotherapies are safe during pregnancy. Recent work, however, concludes that the potential benefit of pharmacotherapies outweigh the risks of continued smoking—especially for those women for whom counselling is not effective. Specifically, the increased cessation rates with the addition of pharmacotherapies yield a higher benefit than exposure of the fetus to carbon monoxide and other toxins if maternal smoking continues.

Reimbursement for smoking cessation interventions during pregnancy is promoted as an important step to address key provider and system level barriers. Recommendations for reimbursement are based on proven effectiveness of smoking cessation interventions and evidence that they are cost effective, especially during the prenatal period. Every dollar spent on smoking cessation interventions for a pregnant smoker saves $3 in neonatal costs and $6 in long term care costs for infants with disabilities caused from smoking.

Although Medicaid is a federally mandated programme, states have flexibility in their level of coverage beyond the basic benefit package. Smoking cessation interventions are not in the basic benefit package. States may elect to decrease Medicaid benefits as a short term solution in response to budget shortfalls or as a way to balance increasing demand. The challenging fiscal situation in states requires evaluation of how Medicaid resources can be applied most effectively to promote health. Although the economic case to promote coverage of smoking cessation interventions is a strong one, a limited number of studies have addressed the effect of incremental increases in coverage.

The purpose of this study was to evaluate the association between levels of Medicaid coverage for prenatal smoking cessation interventions on smoking. We used Pregnancy Risk Assessment Monitoring System (PRAMS) data from 15 states to assess if: (1) quitting during pregnancy, and (2) maintaining cessation after delivery was associated with the level of state Medicaid coverage for smoking cessation interventions.

METHODS

Study population

PRAMS provides population based, state specific data for a variety of maternal behaviours around the time of pregnancy with linked information from birth certificates. PRAMS was
established in 1987 by the Centers for Disease Control and Prevention (CDC). In each participating state, 100–200 new mothers are selected each month from live birth certificates using a stratified systematic process with over-sampling of women with specific risks or characteristics (for example, low birth weight infants, mother’s race). These women receive a mailed questionnaire between two and six weeks after delivery. Non-responders receive up to two repeat mailings and, if necessary, telephone contact. Response rates generally range from 70–80%. To adjust for over-sampling, the PRAMS data from each state are weighted so it is representative of all women giving birth within the selected time period.

We used data collected in 1998-2000 from 15 states that participated in PRAMS: Alaska, Alabama, Arkansas, Colorado, Florida, Illinois, Louisiana, Maine, North Carolina, New Mexico, New York (excluding New York City), Oklahoma, South Carolina, Washington, and West Virginia. Among the 77 981 respondents, 32 272 women reported that their prenatal care was covered by Medicaid (41%). We defined Medicaid coverage as a combined variable including women who had Medicaid before pregnancy, prenatal care coverage by Medicaid, and prenatal care paid by a state specific programme (for example, Medipass). Among the 32 272 women with Medicaid, 20 287 had complete responses to the questions regarding smoking before, during, and after pregnancy (63%). The 7513 women whose prenatal care was paid by Medicaid, who had complete smoking data, and who reported smoking before pregnancy were the study population for this analysis. Because this study used a secondary source for data with no attached identifiers, the Biomedical Institutional Review Board of the University of North Carolina at Chapel Hill deemed it exempt from review.

**Study variables**

The main outcomes for this study included: (1) quitting among women who smoked before pregnancy; and (2) maintaining cessation after delivery among women who quit smoking during pregnancy. Women were considered to be smokers if they reported smoking before pregnancy. Women who reported no smoking at some later point during their pregnancy were considered to be quitters. Among those who stopped smoking during pregnancy (quitters), those who reported no smoking after pregnancy at the PRAMS post-partum follow up (mean time to follow up 4.1 months) were considered to have maintained cessation after delivery. In addition to our two main outcomes, we examined whether participants reported discussion of smoking information with prenatal providers. Women were considered to have discussed smoking cessation if they responded affirmatively to the PRAMS question: “During any of your prenatal visits, did a doctor, nurse or other healthcare worker talk with you about cigarette smoking?”

The main independent variable was state level of Medicaid coverage from smoking cessation services in 1998. Coverage for the following smoking cessation interventions was considered: over the counter medications (for example, nicotine gum, nicotine patch, or any combination), prescriptions (for example, bupropion, spray, inhaler, or any combination), and counselling (group, individual, telephone, or any combination). The level of coverage in each state included in this analysis was obtained from work by Schaufeli, Barker, and Orleans. We grouped coverage into three categories of extensive, some, or none. States with coverage for both counselling (individual, group, or both) and pharmacotherapies (over the counter, prescription, or both) were classified as extensive. States with coverage for any kind of either counselling or pharmacotherapies (over the counter or prescription) for tobacco dependence were classified as some. States with no coverage for smoking cessation interventions were classified as none. We chose to use the level of Medicaid coverage as reported in 1998 to assign states into the three levels of coverage because no state’s coverage was worse in 2000 than 1998, and only four states had increased coverage in 2000. We assumed that increased coverage in 2000 would not necessarily have been adopted immediately at the practice level. Other independent variables of interest included maternal characteristics (for example, age, education level, employment, race/ethnicity, marital status), level of prenatal care, and previous reproductive history (for example, parity, previous preterm birth, previous low birthweight birth).

**Statistical analysis**

We used separate bivariate analyses to assess the relationship of level of state Medicaid coverage (extensive, some, none) to each of our two outcomes: (1) quit smoking during pregnancy (quitters), and (2) maintained cessation after delivery (maintainers). We used a χ² test to examine if the percentage of women for each outcome differed by level of Medicaid coverage. To assess whether any observed associations between Medicaid coverage and each outcome might be confounded by other factors, we compared other characteristics of the women to see if they were unequally distributed by level of Medicaid coverage. These variables included maternal age, marital status, race/ethnicity, education, parity, previous low birth weight, and previous preterm birth. We fit separate logistic regression models for each outcome. Each model included Medicaid coverage and all potential covariates. Since our definition of coverage was based on state, and women from the same state may have other factors contributing to observed differences in outcomes, we also included state in our analyses as a random effect. To assess confounding, we compared β estimates for Medicaid coverage for each outcome with and without potential confounders. If the β estimates for Medicaid coverage did not change (> 10%) when covariates were dropped, these covariates were not included in the final models. Using the β estimates from the final logistic regression models, we estimated odds ratios and adjusted proportions (reported as percentages) by Medicaid coverage for each outcome. All analyses were performed using the survey commands from Stata 8.2 for weighted analysis to handle the complexity of our data. In each of our two models including all potential covariates. Since our definition of coverage was based on state, and women from the same state may have other factors contributing to observed differences in outcomes, we also included state in our analyses as a random effect. To assess confounding, we compared β estimates for Medicaid coverage for each outcome with and without potential confounders. If the β estimates for Medicaid coverage did not change (> 10%) when covariates were dropped, these covariates were not included in the final models. Using the β estimates from the final logistic regression models, we estimated odds ratios and adjusted proportions (reported as percentages) by Medicaid coverage for each outcome. All analyses were performed using the survey commands from Stata 8.2 for weighted analysis to handle the complexity of our data. In each model including all potential covariates. Since our definition of coverage was based on state, and women from the same state may have other factors contributing to observed differences in outcomes, we also included state in our analyses as a random effect. To assess confounding, we compared β estimates for Medicaid coverage for each outcome with and without potential confounders. If the β estimates for Medicaid coverage did not change (> 10%) when covariates were dropped, these covariates were not included in the final models. Using the β estimates from the final logistic regression models, we estimated odds ratios and adjusted proportions (reported as percentages) by Medicaid coverage for each outcome.
women most were between the ages of 20–29 (58%), non-Hispanic, white (74%), not currently married (64%), and with an educational level at, or above, graduation from high school (59%) (table 1). Among smokers, 39% quit during pregnancy. Among quitters, 39% maintained cessation after delivery.

In the 15 states in this analysis, eight states (53%) had no coverage, five states (33%) had some coverage, and two states (13%) had extensive coverage in 1998. Table 2 provides the state specific level of Medicaid coverage and proportions of women from each state who reported smoking before pregnancy, quitting during pregnancy, and maintaining cessation after delivery. In 1998, 50% of study women had no smoking cessation coverage from Medicaid, 46% had some coverage, and 4% had extensive coverage. A majority (89%) of women (smokers and non-smokers) reported a prenatal discussion about smoking with their health care provider.

After adjusting for covariates, higher levels of Medicaid coverage in 1998 were associated with an increased likelihood of quitting (table 3). Specifically, 51% of women in states with extensive coverage quit smoking during pregnancy compared to 43% of women in states with some coverage and 39% of women in states with no coverage. Compared to women in states with no coverage, women in states with extensive coverage had 1.6 times the odds of quitting smoking (odd ratio (OR) 1.58, 95% confidence interval (CI) 1.00 to 2.49); women in states with some coverage had 1.2 times the odds of quitting (OR 1.18, 95% CI 1.03 to 1.34). Maintenance of cessation after delivery was associated with extensive levels of Medicaid coverage (table 3). Specifically, 48% of women in states with extensive coverage maintained cessation after delivery, while 37% of women who quit smoking during pregnancy in states with no or some coverage maintained cessation. Compared to women in states with no coverage, women with extensive coverage had 1.6 times the odds of maintaining cessation (OR 1.63, 95% CI 1.04 to 2.56). The odds of maintaining cessation were similar for women in states with some and no coverage (OR 1.02, 95% CI 0.89 to 1.18).

**DISCUSSION**

This work shows the inclusion of prenatal Medicaid coverage for both pharmacotherapies and counselling is associated with higher rates of quitting during pregnancy and maintaining cessation after delivery. Combined with the effectiveness and cost effectiveness of smoking cessation interventions and previous recommendations to provide extensive smoking cessation coverage, this work supports increasing resource allocation to prenatal Medicaid smoking cessation interventions.

For increased reimbursement strategies to be successful, other supporting components are needed to expand the capacity to deliver smoking cessation interventions.
Prenatal Medicaid coverage for both pharmacotherapies and counselling is associated with higher rates of quitting and continued cessation. This suggests policymakers can promote cessation by broadening smoking cessation services in Medicaid prenatal coverage.

Effective smoking interventions for use during pregnancy are available to limit the adverse health and economic impact of smoking during pregnancy. Although the economic case to promote coverage of smoking cessation interventions is a strong one, a limited number of studies have addressed the effect of incremental increases in coverage and none have specifically assessed the influence of increasing coverage for smoking cessation interventions among pregnant women.

In conclusion, this work provides timely evidence regarding the importance of continuing to increase Medicaid reimbursement for smoking cessation interventions as states struggle with critical funding decisions. Without improved resource allocation to provide coverage to pregnant women receiving Medicaid, we are missing an opportunity to affect positively the short and long term maternal and child health status to the women who begin their pregnancy as a smoker.

ACKNOWLEDGEMENTS
This work was supported by Clinical Research Training for Junior Faculty Grant (#CRTG-03-074-01-PBP) from the American Cancer Society. The funding agency was not involved in any aspect of: the design or conduct of the study; collection, management, analysis and interpretation of the data; or preparation, review, and approval of the manuscript.

The authors acknowledge the CDC and the PRAMS Working Group for their dedication to PRAMS. Members of the PRAMS working group include: Alabama – Rhonda Stephens, MPH; Alaska – Kathy Perham-Hester, MS, MPH; Arkansas – Gina Redford, MAP; Colorado – Alyson Shupe, PhD; Florida – Helen Marshall; Georgia – Carol Hoban, MS, MPH; Hawaii – Limin Song, MPH, CHES; Illinois – Theresa Sandidge, MA; Louisiana – Joan Wightkin; Maine – Martha Henson; Maryland – Diana Cheng, MD; Michigan – Yasmina Bourasou, MPH; Minnesota – Jan Jernell; Mississippi – Linda Pendleton, LMSW; Montana – JoAnn Dotson; Nebraska – Jennifer Severe-Ofolaru; New Jersey – Lakota Kruse, MD; New Mexico – Soo Weng, MD, MPH; New York State – Anne Radigan-Garcia; New York City – Candace Mulready, MPH; North Carolina – Paul Buescher, PhD; North Dakota – Sandra Anshet, RN; Ohio – Amy Davis; Oklahoma –Dick Lorenz; Oregon – Ken Rosenberg, MD, MPH; Rhode Island – Sam Viner-Brown; South Carolina – Sylvia Sievers, PhD; Texas – Tanya J. Guthrie, PhD; Utah – Lois Bloebaum; Vermont – Peggy Brozicvic; Washington – Linda Lohdefinck; West Virginia – Melissa Baker, MA; CDC PRAMS Team, Applied Sciences Branch, Division of Reproductive Health

Authors’ affiliations
Petersen*, J M Garrett, K E Hartmann†, Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
C L Melvin† Cecil Sheps Center for Health Services Research, University of North Carolina at Chapel Hill

*Department of Maternal and Child Health, School of Public Health, University of North Carolina at Chapel Hill
†Also Center for Women’s Health Research, and Cecil Sheps Center for Health Services Research, University of North Carolina at Chapel Hill

Competing interests: none declared

Human participation protection: This project was reviewed by the Committee on the Protection of the Rights of Human Subjects at the University of North Carolina at Chapel Hill and was found to be exempt from review since subjects could not be identified from the secondary data source used in this analysis (per number 4 in 45 CFR Part 46 Section 101).

REFERENCES
Comprehensive smoke-free legislation has been in place in New Zealand for over 15 years and for much of that time advertising of tobacco products or the use of tobacco trademarks on goods other than tobacco products has been banned. Despite this legislation, retail products occasionally appear that clearly breach the legislation. The most recent example of such products was found in Dunedin in 2005. In this example, mini-bikes (also referred to as pocket bikes) displayed branding for Lucky Strike and Camel cigarettes. Although it is not clear if British American Tobacco or RJ Reynolds were aware of the use of their product trademark, the trademarks closely resembled those used by the manufacturers. These motorised bikes were manufactured in China and appear to appeal to young males aged 12–13 years and older. The bikes were withdrawn from sale when the retailer was notified of the violation of legislation.

Even in a country with legislation that explicitly removes tobacco brand images and advertising there remains a need to be vigilant for tobacco product promotion, whether this promotion is directly as a result of tobacco manufacturer activity or not.

H Darling
A I Reeder
helen.darling@stonebow.otago.ac.nz